1. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2017;69(11):1465-508.
2. Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, Conte MS, et al. The natural history of untreated severe or critical limb ischemia. Journal of vascular surgery. 2015;62(6):1642-51. e3.
3. Steunenberg SL, Raats JW, Te Slaa A, de Vries J, van der Laan L. Quality of life in patients suffering from critical limb ischemia. Annals of vascular surgery. 2016;36:310-9.
4. Reinecke H, Unrath M, Freisinger E, Bunzemeier H, Meyborg M, Lüders F, et al. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. European heart journal. 2015;36(15):932-8.
5. Hioki H, Miyashita Y, Miura T, Ebisawa S, Motoki H, Izawa A, et al. Prognostic improvement by multidisciplinary therapy in patients with critical limb ischemia. Angiology. 2015;66(2):187-94.
6. Pignon B, Sevestre M-A, Kanagaratnam L, Pernod G, Stephan D, Emmerich J, et al. Autologous Bone Marrow Mononuclear Cell Implantation and Its Impact on the Outcome of Patients With Critical Limb Ischemia―Results of a Randomized, Double-Blind, Placebo-Controlled Trial―. Circulation Journal. 2017;81(11):1713-20.
7. Poole J, Mavromatis K, Binongo JN, Khan A, Li Q, Khayata M, et al. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial. Jama. 2013;310(24):2631-9.
8. Fowkes FGR, Price JF. Gene therapy for critical limb ischaemia: the TAMARIS trial. The Lancet. 2011;377(9781):1894-6.
9. Han SW, Vergani Junior CA, Reis PEO. Is gene therapy for limb ischemia a reality? Jornal Vascular Brasileiro. 2020;19.
10. Han SW, Vergani Junior CA, Ocke Reis PE. Is gene therapy for limb ischemia a reality? Jornal Vascular Brasileiro. 2020;19.
11. Da Cunha FF, Martins L, Martin PKM, Stilhano RS, Gamero EJP, Han SW. Comparison of treatments of peripheral arterial disease with mesenchymal stromal cells and mesenchymal stromal cells modified with granulocyte and macrophage colony-stimulating factor. Cytotherapy. 2013;15(7):820-9.
12. Khajeh S, Razban V, Talaei-Khozani T, Soleimani M, Asadi-Golshan R, Dehghani F, et al. Enhanced chondrogenic differentiation of dental pulp-derived mesenchymal stem cells in 3D pellet culture system: effect of mimicking hypoxia. Biologia. 2018;73(7):715-26.
13. Razban V, Khajeh S, Alaee S, Mostafavi-Pour Z, Soleimani M. Tube formation potential of BMSCs and USSCs in response to HIF-1α overexpression under hypoxia. Cytology and Genetics. 2018;52(3):236-44.
14. Cortez-Toledo E, Rose M, Agu E, Dahlenburg H, Yao W, Nolta JA, et al. Enhancing retention of human bone marrow mesenchymal stem cells with prosurvival factors promotes angiogenesis in a mouse model of limb ischemia. Stem cells and development. 2019;28(2):114-9.
15. Petrenko Y, Vackova I, Kekulova K, Chudickova M, Koci Z, Turnovcova K, et al. A comparative analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential. Scientific reports. 2020;10(1):1-15.
16. Razban V, Khajeh S, Lotfi AS, Mohsenifar A, Soleimani M, Khoshdel A, et al. Engineered heparan sulfate-collagen IV surfaces improve human mesenchymal stem cells differentiation to functional hepatocyte-like cells. Journal of Biomaterials and Tissue Engineering. 2014;4(10):811-22.
17. Fierro FA, Kalomoiris S, Sondergaard CS, Nolta JA. Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy. Stem Cells. 2011;29(11):1727-37.
18. Altaner C, Altanerova V, Cihova M, Hunakova L, Kaiserova K, Klepanec A, et al. Characterization of mesenchymal stem cells of “no-options” patients with critical limb ischemia treated by autologous bone marrow mononuclear cells. PLoS One. 2013;8(9).
19. Nammian P, Asadi-Yousefabad S-L, Daneshi S, Sheikhha MH, Tabei SMB, Razban V. Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy. Stem Cell Research & Therapy. 2021;12(1):1-15.
20. Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. Journal of neuroimmunology. 2010;227(1-2):185-9.
21. Mohamed SA, Howard L, McInerney V, Hayat A, Krawczyk J, Naughton S, et al. Autologous bone marrow mesenchymal stromal cell therapy for “no-option” critical limb ischemia is limited by karyotype abnormalities. Cytotherapy. 2020.
22. Ferreira JR, Teixeira GQ, Santos SG, Barbosa MA, Almeida-Porada G, Gonçalves RM. Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning. Frontiers in immunology. 2018;9:2837.
23. Mao AS, Özkale B, Shah NJ, Vining KH, Descombes T, Zhang L, et al. Programmable microencapsulation for enhanced mesenchymal stem cell persistence and immunomodulation. Proceedings of the National Academy of Sciences. 2019;116(31):15392-7.
24. Zhang J, Sun X-J, Chen Ja, Hu ZW, Wang L, Gu DM, et al. Increasing the miR-126 expression in the peripheral blood of patients with diabetic foot ulcers treated with maggot debridement therapy. Journal of Diabetes and its Complications. 2017;31(1):241-4.
25. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, et al. A microRNA signature of hypoxia. Molecular and cellular biology. 2007;27(5):1859-67.
26. Dang LT, Lawson ND, Fish JE. MicroRNA control of vascular endothelial growth factor signaling output during vascular development. Arteriosclerosis, thrombosis, and vascular biology. 2013;33(2):193-200.
27. Caporali A, Emanueli C. MicroRNA regulation in angiogenesis. Vascular pharmacology. 2011;55(4):79-86.
28. Nammian P, Razban V, Tabei SMB, Asadi-Yousefabad S-L. MicroRNA-126: Dual Role in Angiogenesis Dependent Diseases. Current pharmaceutical design. 2020.
29. Zhou J, Li Y-S, Nguyen P, Wang K-C, Weiss A, Kuo Y-C, et al. Regulation of vascular smooth muscle cell turnover by endothelial cell–secreted microRNA-126: role of shear stress. Circulation research. 2013;113(1):40-51.
30. Li Y, Tian L, Sun D, Yin D. Curcumin ameliorates atherosclerosis through upregulation of miR‐126. Journal of cellular physiology. 2019.
31. Fish JE, Santoro MM, Morton SU, Yu S, Yeh R-F, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Developmental cell. 2008;15(2):272-84.
32. van Solingen C, Seghers L, Bijkerk R, Duijs JM, Roeten MK, van Oeveren‐Rietdijk AM, et al. Antagomir‐mediated silencing of endothelial cell specific microRNA‐126 impairs ischemia‐induced angiogenesis. Journal of cellular and molecular medicine. 2009;13(8a):1577-85.
33. Krishna SM, Omer SM, Li J, Morton SK, Jose RJ, Golledge J. Development of a two-stage limb ischemia model to better simulate human peripheral artery disease. Scientific reports. 2020;10(1):1-16.
34. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7.
35. Pham LH, Vu NB, Van Pham P. The subpopulation of CD105 negative mesenchymal stem cells show strong immunomodulation capacity compared to CD105 positive mesenchymal stem cells. Biomedical Research and Therapy. 2019;6(4):3131-40.
36. Lv F-J, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem cells. 2014;32(6):1408-19.
37. Maacha S, Sidahmed H, Jacob S, Gentilcore G, Calzone R, Grivel J-C, et al. Paracrine mechanisms of mesenchymal stromal cells in angiogenesis. Stem cells international. 2020;2020.
38. Watt SM, Gullo F, van der Garde M, Markeson D, Camicia R, Khoo CP, et al. The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential. British medical bulletin. 2013;108(1):25-53.
39. Tao H, Han Z, Han ZC, Li Z. Proangiogenic features of mesenchymal stem cells and their therapeutic applications. Stem cells international. 2016;2016.
40. Chen J-J, Zhou S-H. Mesenchymal stem cells overexpressing MiR-126 enhance ischemic angiogenesis via the AKT/ERK-related pathway. Cardiology journal. 2011;18(6):675-81.
41. Kong R, Gao J, Ji L, Zhao D. MicroRNA-126 promotes proliferation, migration, invasion and endothelial differentiation while inhibits apoptosis and osteogenic differentiation of bone marrow-derived mesenchymal stem cells. Cell Cycle. 2020;19(17):2119-38.
42. Chang L, Liang J, Xia X, Chen X. miRNA‐126 enhances viability, colony formation, and migration of keratinocytes HaCaT cells by regulating PI3 K/AKT signaling pathway. Cell biology international. 2019;43(2):182-91.
43. Sheng L, Mao X, Yu Q, Yu D. Effect of the PI3K/AKT signaling pathway on hypoxia‑induced proliferation and differentiation of bone marrow‑derived mesenchymal stem cells. Experimental and therapeutic medicine. 2017;13(1):55-62.
44. Kang I, Lee B-C, Choi SW, Lee JY, Kim J-J, Kim B-E, et al. Donor-dependent variation of human umbilical cord blood mesenchymal stem cells in response to hypoxic preconditioning and amelioration of limb ischemia. Experimental & molecular medicine. 2018;50(4):1-15.
45. Hu W, Jiang J, Yang F, Liu J. The impact of bone marrow-derived mesenchymal stem cells on neovascularisation in rats with brain injury. Folia Neuropathol. 2018;56:112-23.
46. Li GC, Zhang HW, Zhao QC, Sun L, Yang JJ, Hong L, et al. Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor β1. Oncology letters. 2016;11(2):1089-94.
47. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem cells. 2007;25(10):2648-59.
48. Trivanović D, Jauković A, Popović B, Krstić J, Mojsilović S, Okić-Djordjević I, et al. Mesenchymal stem cells of different origin: comparative evaluation of proliferative capacity, telomere length and pluripotency marker expression. Life Sciences. 2015;141:61-73.
49. Shen C-C, Chen B, Gu J-T, Ning J-L, Chen L, Zeng J, et al. The angiogenic related functions of bone marrow mesenchymal stem cells are promoted by CBDL rat serum via the Akt/Nrf2 pathway. Experimental cell research. 2016;344(1):86-94.
50. Wang J, Wang Y, Wang S, Cai J, Shi J, Sui X, et al. Bone marrow-derived mesenchymal stem cell-secreted IL-8 promotes the angiogenesis and growth of colorectal cancer. Oncotarget. 2015;6(40):42825.
51. Fam NP, Verma S, Kutryk M, Stewart DJ. Clinician guide to angiogenesis. Circulation. 2003;108(21):2613-8.
52. Ullah M, Liu DD, Thakor AS. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. Iscience. 2019;15:421-38.
53. Ye L, Peng Y, Mo J, Yao Y. MiR-126 enhances VEGF expression in induced pluripotent stem cell-derived retinal neural stem cells by targeting spred-1. International Journal of Clinical and Experimental Pathology. 2018;11(2):1023.
54. Qu Q, Bing W, Meng X, Xi J, Bai X, Liu Q, et al. Upregulation of miR-126-3p promotes human saphenous vein endothelial cell proliferation in vitro and prevents vein graft neointimal formation ex vivo and in vivo. Oncotarget. 2017;8(63):106790.
55. Li X, Zhou J, Liu Z, Chen J, Lü S, Sun H, et al. A PNIPAAm-based thermosensitive hydrogel containing SWCNTs for stem cell transplantation in myocardial repair. Biomaterials. 2014;35(22):5679-88.
56. Tano N, Kaneko M, Ichihara Y, Ikebe C, Coppen SR, Shiraishi M, et al. Allogeneic mesenchymal stromal cells transplanted onto the heart surface achieve therapeutic myocardial repair despite immunologic responses in rats. Journal of the American Heart Association. 2016;5(2):e002815.
57. Saldaña L, Bensiamar F, Vallés G, Mancebo FJ, García-Rey E, Vilaboa N. Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors. Stem cell research & therapy. 2019;10(1):1-15.
58. Weiss ARR, Dahlke MH. Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Frontiers in Immunology. 2019;10:1191.
59. Araña M, Gavira JJ, Peña E, González A, Abizanda G, Cilla M, et al. Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. Biomaterials. 2014;35(1):143-51.
60. Chen L, Wang J, Wang B, Yang J, Gong Z, Zhao X, et al. MiR-126 inhibits vascular endothelial cell apoptosis through targeting PI3K/Akt signaling. Annals of hematology. 2016;95(3):365-74.
61. Bronckaers A, Hilkens P, Martens W, Gervois P, Ratajczak J, Struys T, et al. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. Pharmacology & therapeutics. 2014;143(2):181-96.
62. Qu M-J, Pan J-J, Shi X-J, Zhang Z-J, Tang Y-H, Yang G-Y. MicroRNA-126 is a prospective target for vascular disease. Neuroimmunology and Neuroinflammation. 2018;5.
63. Ji J-S, Xu M, Song J-J, Zhao Z-W, Chen M-J, Chen W-Q, et al. Inhibition of microRNA-126 promotes the expression of Spred1 to inhibit angiogenesis in hepatocellular carcinoma after transcatheter arterial chemoembolization: in vivo study. OncoTargets and therapy. 2016;9:4357.